iba all sections
Brain
DOPACIS®

Medicinal product for diagnostic use only. Indicated for use with positron emission tomography in neurology and oncology. Please, refer to the SPC.

Thyroid
CAPSION®
  • Treatment of Graves’ disease, toxic multinodular goitre or autonomous nodules
  • Treatment of papillary and follicular thyroid carcinoma including metastatic disease

I-123-S-2

Functional and morphological study of the thyroid gland


I-131-S-1
Diagnostic
  • Estimation of thyroid uptake and effective half life
  • Identification of thyroid remnant and metastases (after ablation)
Therapy
  • Treatment of Graves’ disease, toxic multinodular goitre or autonomous nodules
  • Treatment of papillary and follicular thyroid carcinoma including metastatic disease

I-131-S-2
Diagnostic
  • Estimation of thyroid uptake and effective half life
  • Management of thyroid carcinoma : identification of thyroid remnant and metastases (after ablation)
Therapy
  • Treatment of Graves' disease, toxic multinodular goitre or autonomous nodules
  • Treatment of papillary and follicular thyroid carcinoma including metastatic disease
Sentinel nodes
NANOCIS®
  • Imaging and detection of sentinel lymph node : 5 to 200 MBq: activity and volume injected depending on the indication.
  • Lymphatic flow scintigraphy : 20 to 200 MBq in 0.2 to 0.3 mL / site Vol max/injection site: 0.5 mL
  • Gastro Oesophageal Reflux : 3.5 to 12 MBq
Lung
PENTACIS®
Intravenous use:
  • Renal glomerular filtration:     1.8 to 3.7 MBq (plasma)
  • Renal glomerular filtration:     37 to 370 MBq (scanning)
  • Brain scanning:     185 to 740 MBq
Oral use: Study of gastro-oesophageal reflux and gastric
  • emptying:     10 to 20 MBq

PULMOCIS®
  • Pulmonary perfusion scintigraphy
  • Venoscintigraphy

VENTIBOX

LEAD SHIELDED BOX FOR ONE VENTICIS® II SYSTEM


VENTICIS® II
Venticis® is an aerosol generator intended for
  • Study of pulmonary ventilation
  • Study of alveolar-capillary permeability
Liver
PHYTACIS®

Hepatic scintigraphy :     37 to 100 MBq

Bones
CISNAF®

Medicinal product for diagnostic use only. Indicated for use with positron emission tomography (PET) in bone imaging.
Please, refer to the SPC.


OSTEOCIS®
Bone scintigraphy
  • 300 to 700 MBq / 50 or 70kg adult
  • 500 MBq average activity

TECEOS®

Bone scintigraphy 500 MBq (300 - 700 MBq)


QUADRAMET®

Relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium (99mTc)-labelled biphosphonates on bone scan

Cardio-vascular system
ANGIOCIS®
  • Angiocardioscintigraphy
  • Organ perfusion and vascular abnormality imaging
  • Diagnosis and localisation of occult gastro-intestinal bleeding Activity injected for blood pool scintigraphy (740 - 925 MBq)

SERALB-125
  • Determination of plasma volume and total blood volume
  • Examination of albumin turnover.

STAMICIS®

Adults
The suggested activity range for intravenous use to a patient of average weight (70 kg) is:
Myocardial perfusion scintigraphy: 400-900 MBq
Assessment of global ventricular function: 600-800 MBq injected as a bolus.

For diagnosis of ischaemic heart disease two injections (stress and rest) are required in order to differentiate transiently from persistently reduced myocardial uptake.
The recommended activity range for diagnosis of ischaemic heart disease according to the European procedural guideline is:

  • Two-day protocol: 600–900 MBq/study
  • One-day protocol: 400–500 MBq

for the first injection, three times more for the second injection. Not more than a total of 2000 MBq should be administered for a one-day protocol and 1800 MBq for a two-day-protocol. For a one day protocol, the two injections (stress and rest) should be done at least two hours apart but may be performed in either order.
After the stress injection, exercise should be encouraged for an additional one minute (if possible).
For diagnosis of myocardial infarction one injection at rest may be sufficient.
The injection of activities greater than local DRLs (Diagnostic Reference Levels) should be justified.
Scinti-mammography for the detection of suspected breast cancer: 750-1000 MBq injected as a bolus in the arm opposite to the lesion.
Localisation of hyperfunctioning parathyroid tissue:
200–1000 MBq injected as a bolus (the activity used should in every case be as low as reasonably practical). The typical activity is 740 MBq.

Children and adolescents:
For pediatric use, please refer to the full SPC.


TL-201-S-1
  • Myocardial scintigraphy in the evaluation of coronary perfusion and cellular viability.
  • Scintigraphy of the muscles.
  • Parathyroid scintigraphy.
  • Thallium avid tumour visualisation in different organs, especially for the brain tumours and thyroid tumours and metastases.

VASCULOCIS®
  1. Static blood pool imaging :     111 to 185 MBq
  2. Angiography :     370 to 740 MBq
  3. Circulation, blood flow studies :     18.5 to 185 MBq
  4. Ventriculography :     185 to 925 MBq
Adrenal glands/Kidneys
NORCHOL-131
  • Diagnostic evaluation of the functional state of adrenal cortical tissue
  • Differentiation between metastatic disease to the adrenals (“cold area”) and non-malignant adrenal enlargement in cancer patients
  • Detection of remnants of functioning tissue in hypercortisonism after adrenalectomy, or of ectopic endocrine tissue
  • Detection and follow-up of euadrenal tumours

PENTACIS®
Intravenous use:
  • Renal glomerular filtration:     1.8 to 3.7 MBq (plasma)
  • Renal glomerular filtration:     37 to 370 MBq (scanning)
  • Brain scanning:     185 to 740 MBq
Oral use: Study of gastro-oesophageal reflux and gastric
  • emptying:     10 to 20 MBq

RENOCIS®
Static planar or tomographic renal imaging :
  • Morphological studies of renal cortex
  • Individual kidney function
  • Location of ectopic kidney
30 to 120 MBq

EDICIS™ 2 mg
Dynamic scintigraphy in adults for:
  • Evaluation of nephropathies and uropathies especially for assessing relative kidney function, renal morphology, and renal perfusion.
  • Drainage of the upper urinary tract.
The recommended activity for a patient of 70 kg average body weight is between 90 MBq and 120 MBq injected intravenously
Lymphatic system
NANOCIS®
  • Imaging and detection of sentinel lymph node : 5 to 200 MBq: activity and volume injected depending on the indication.
  • Lymphatic flow scintigraphy : 20 to 200 MBq in 0.2 to 0.3 mL / site Vol max/injection site: 0.5 mL
  • Gastro Oesophageal Reflux : 3.5 to 12 MBq
Joints (various sizes)
ERMM-1

Treatment of rheumatoid mono or oligo-arthritis involving one or few of the small joints of the hands and feet following failure of intra-articular corticosteroid therapy or when the latter is contra-indicated


RE-186-MM-1
  • Treatment of rheumatoid mono or oligo arthritis involving mediumsized joints (shoulders, elbows, wrists, ankles, hips) and particularly rheumatoid polyarthritis
  • Treatment of haemophilic or chronic arthropathy associated with articular chondrocalcinosis.

YMM-1

Therapeutic irradiation of synovial hypertrophy of knee joints mainly for mono- or oligo-articular arthritis of chronic inflammatory rheumatism particularly rheumatoid polyarthritis

Inflammation/infection
GA-67-MM-1
  • Non-specific tumor imaging and/or localising agent
  • Localisation of inflammatory lesions

SCINTIMUN® 1 mg

In conjunction with other appropriate imaging modalities determination of the location of inflammation/infection peripheral bone in adults with suspected osteomyelitis (400-800 MBq).
Should not be used for the diagnosis of diabetic foot infection

Others
TEKCIS™
Precalibrated activity
  • 2-4-6-8-10-12-16-20-25-50 GBq
Therapy
  • Labelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such solution.
  • Thyroid scintigraphy.
  • Salivary gland scintigraphy.
  • Location of ectopic gastric mucosa (Meckel's diverticulum).
  • Lacrimal duct scintigraphy.